Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eshoo Amendment Would Allow Substitution Of Biosimilars Without Health Care Provider Okay

This article was originally published in The Pink Sheet Daily

Executive Summary

Few differences with Senate HELP bill remain, as House Democrat adopts that panel's language on products available for data exclusivity.

You may also be interested in...



Road To Biosimilar Interchangeability Could Be Through Market Experience

Demonstrating that a biosimilar is interchangeable with its reference product may be a subject for post-market studies rather than clinical trials, according to Kathleen Sanzo, partner at Morgan, Lewis and Bockius

Road To Biosimilar Interchangeability Could Be Through Market Experience

Demonstrating that a biosimilar is interchangeable with its reference product may be a subject for post-market studies rather than clinical trials, according to Kathleen Sanzo, partner at Morgan, Lewis and Bockius

Follow-on Biologics Go Back To The Future: Senate Cmte. Endorses 12 Years of Brand Exclusivity

Hatch/Enzi/Hagan amendment retains the number from last year's bill, but a fight on floor seems possible.

Topics

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel